KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Account Payables: 2018-2025

Historic Change in Account Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $2.9 million.

  • Esperion Therapeutics' Change in Account Payables rose 122.72% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year increase of 394.29%. This contributed to the annual value of $12.4 million for FY2024, which is 43.26% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Change in Account Payables stood at $2.9 million, which was up 10.81% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Change in Account Payables registered a high of $27.8 million during Q1 2025, and its lowest value of -$21.6 million during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' Change in Account Payables averaged around $5.0 million, with its median value being $2.9 million (2025).
  • Per our database at Business Quant, Esperion Therapeutics' Change in Account Payables plummeted by 2,242.74% in 2022 and then spiked by 907.07% in 2025.
  • Esperion Therapeutics' Change in Account Payables (Quarterly) stood at -$3.3 million in 2021, then soared by 236.99% to $4.5 million in 2022, then increased by 23.02% to $5.5 million in 2023, then skyrocketed by 69.04% to $9.3 million in 2024, then skyrocketed by 122.72% to $2.9 million in 2025.
  • Its Change in Account Payables was $2.9 million in Q3 2025, compared to $2.6 million in Q2 2025 and $27.8 million in Q1 2025.